Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Zhaoke OphthalmologyHKSE:06622 +1.61%47 Current Ratio is 4.18 as of Dec. 2025, which is 22% below its 10-year median of 5.33. GuruFocus rates HKSE:06622 with a GF Score™ of 47/100 and a GF Value™ of HK$2.60 (Fairly Valued). The stock has 5 warning signs investors should review. Among 1,410 Biotechnology companies, Zhaoke Ophthalmology ranks better than 52.06% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Zhaoke Ophthalmology's current ratio for the quarter that ended in Dec. 2025 was 4.18.
Zhaoke Ophthalmology has a current ratio of 4.18. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for Zhaoke Ophthalmology's Current Ratio or its related term are showing as below:
HKSE:06622'
s Current Ratio Range Over the Past 10 Years
Min: 2.06 Med: 5.33 Max: 24.82
Current: 4.18
During the past 7 years, Zhaoke Ophthalmology's highest Current Ratio was 24.82. The lowest was 2.06. And the median was 5.33.
HKSE:06622's Current Ratio is ranked better than 52.06% of 1410
companies
in the Biotechnology industry
Industry Median: 3.89
vs HKSE:06622: 4.18
Zhaoke Ophthalmology (HKSE:06622) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Zhaoke Ophthalmology Current Ratio Related Terms
Zhaoke Ophthalmology Current Ratio Historical Data
* Premium members only.
The historical data trend for Zhaoke Ophthalmology's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HKSE:06622 vs VRTX, REGN, MRNA: Current Ratio Comparison
For the Biotechnology subindustry, Zhaoke Ophthalmology's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zhaoke Ophthalmology Current Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Zhaoke Ophthalmology's Current Ratio distribution charts can be found below:
* The bar in red indicates where Zhaoke Ophthalmology's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zhaoke Ophthalmology (HKSE:06622) has a Current Ratio of 4.18 as of Dec. 2025. This is 22% below median its historical median of 5.33. Over the past decade, Zhaoke Ophthalmology's Current Ratio has ranged from 2.06 to 24.82. According to the industry distribution chart, Zhaoke Ophthalmology ranks #676 out of 1410 companies in the Biotechnology industry, placing it in the top 47.9%.
Is Zhaoke Ophthalmology's Current Ratio too high?
Zhaoke Ophthalmology's current Current Ratio of 4.18 is 22% below median its 10-year median of 5.33. Over the past 10 years, this metric has ranged from a low of 2.06 to a high of 24.82. The Biotechnology industry median Current Ratio is 3.89. Zhaoke Ophthalmology's value of 4.18 is 7.5% above this industry median. Based on the distribution chart, Zhaoke Ophthalmology ranks #676 out of 1410 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Zhaoke Ophthalmology has a GF Score™ of 47/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Zhaoke Ophthalmology's Current Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Zhaoke Ophthalmology ranks #676 out of 1410 companies for Current Ratio. This puts Zhaoke Ophthalmology in the upper half of its industry. The industry median Current Ratio is 3.89. Zhaoke Ophthalmology's value of 4.18 is 7.5% above this benchmark. Historically, Zhaoke Ophthalmology's own Current Ratio has ranged from 2.06 to 24.82 over the past decade. While the company's 10-year median is 5.33 vs. the industry median of 3.89, Zhaoke Ophthalmology has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Biotechnology company?
The median Current Ratio among Biotechnology companies is 3.89, based on 1,410 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Zhaoke Ophthalmology's current Current Ratio of 4.18 is 7.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Current Ratio is 3.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zhaoke Ophthalmology's current Current Ratio is 4.18, which is 22% below median its own 10-year median of 5.33. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zhaoke Ophthalmology stock overvalued right now?
Based on GuruFocus' analysis, Zhaoke Ophthalmology (HKSE:06622) is currently considered Fairly Valued. The stock's GF Value™ is HK$2.60, compared to a current price of HK$2.53 — trading 2.7% below its estimated fair value. The current Current Ratio is 4.18, which is 22% below median its 10-year median of 5.33 and 7.5% above the Biotechnology industry median of 3.89. Zhaoke Ophthalmology's overall GF Score™ is 47/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Zhaoke Ophthalmology (HKSE:06622), the current Current Ratio is 4.18 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zhaoke Ophthalmology (HKSE:06622) Overvalued in 2026?
Based on GuruFocus' analysis, Zhaoke Ophthalmology stock appears to be undervalued.
The current stock price of HK$2.53 is trading 2.7% below its estimated GF Value™ of HK$2.60.
GuruFocus considers Zhaoke Ophthalmology to be Fairly Valued.
Key valuation signals for HKSE:06622:
Current Ratio: 4.18 (22% below median its 10-year median of 5.33)
GF Value™: HK$2.60 vs. price of HK$2.53 (2.7% below fair value)
Industry Position: 7.5% above the Biotechnology median (#676 of 1410)
No single metric tells the full story. See the HKSE:06622 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zhaoke Ophthalmology Ltd is an ophthalmic pharmaceutical company dedicated to the research, development, manufacture and commercialization of therapies that address unmet medical needs. The company has three flagship drug assets progressing towards potential market approval: NVK002 for myopia, CsA Ophthalmic Gel for DED and TAB014 for wAMD; and two drug assets in the clinical stage BRIMOCHOL PF for presbyopia and ZKY001 for corneal epithelial defects. Geographically the company operates in Hong Kong, Chinese Mainland, South Korea, and Others, of which it generates maximum revenue from Chinese Mainland.
47GF Score
Get the complete analysis for HKSE:06622
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:06622 has been successfully added to your 
